DBP introduces SA-101, a new drug candidate for the treatment of solid tumors, that is now entering the preclinical stage of development.

DPB announced today that SA-101 has been selected as its next drug candidate. Hereby, SA-101 is officially entering the preclinical phase of drug development, which is the first step for a successful drug candidate towards marketing. SA-101 targets solid tumors and is based on a new drug delivery mechanism. "We are building a portfolio of several drug candidates for those types of cancers that currently lack good treatments, said company CEO Igor Lokot. Through our broad yet focused product strategy with several oncological drug candidates in the pipeline in different stages of